M3TRIQ Sdn. Bhd

M3TRIQ Sdn. Bhd, located in Kuala Lumpur, Malaysia, specializes in advanced AI-driven solutions for antibody transformation, providing innovative technologies to enhance drug development and bioinformatics. Founded in 2025 in Kuala Lumpur, Malaysia, M3TRIQ Sdn. Bhd focuses on developing an AI system that adapts antibodies across species.

The company raised MYR 110,000 in pre-seed funding from investor Antler on August 6, 2025, marking its first investment round. M3TRIQ is not known to have any subsidiaries or to have undergone significant business pivots since its inception. M3TRIQ's core offerings center around its innovative multi-agent AI system, AMPSA (Agentic Multi-species Paratope-preserving Species Adapter), which enables the transformation of antibodies from various source species to any target species without compromising binding efficacy. This technology is designed for a broad array of applications, including drug development, protein engineering, and molecular discovery.

The system supports species-agnostic adaptation, efficiently preserving critical antigen-binding regions while simultaneously optimizing framework regions to minimize immunogenicity. M3TRIQ serves a diverse client base, including pharmaceutical companies and biotechnology firms globally, with applications across North America, Europe, and Asia. M3TRIQ generates revenue through a combination of partnership agreements and direct client engagements, focusing primarily on B2B transactions. The company implements a structured pricing model that may involve subscription services for ongoing access to its AI-driven platforms, alongside fees for customized project-based work.

Notable offerings include the AMPSA system for cross-species antibody adaptation and comprehensive solutions for protein design and drug discovery, which are aimed at clients in the biopharmaceutical sector. Through these structured transaction models, M3TRIQ capitalizes on its advanced technological capabilities, driving revenue while providing tailored solutions to meet the specific needs of its clientele. M3TRIQ plans to leverage its recent funding of MYR 110,000 to enhance the development of its AMPSA system and expand its market reach. The company aims to introduce new products that focus on optimizing drug discovery and protein engineering processes by 2026.

Additionally, M3TRIQ is targeting expansion into European and North American markets by the end of 2026, broadening its client base and enhancing its scientific capabilities.